Hormonal
Once-weekly semaglutide treatment is associated with a significant increase in pulse rate compared to once-daily sitagliptin.
If you take semaglutide, expect your resting heart rate to increase slightly (by about 3 beats per minute) compared to if you took sitagliptin. This is a known side effect. While usually not dangerous, it is worth monitoring, especially if you have underlying heart conditions.
however, there was an observed increase in pulse rate (WMD: 3.33; 95% ci: 1.61, 5.06, p-value: <0.00001; i2: 100%) associated with semaglutide treatment.
Why this rating
Meta-analysis of 3 RCTs, high heterogeneity (I2=100%).
Source
Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
Tirath Patel et al. · Annals of Medicine · 2023
DOI 10.1080/07853890.2023.2239830
More from this paper
- Once-weekly semaglutide (0.5 mg and 1.0 mg) as an add-on to metformin significantly improves glycemic control (HbA1c), reduces body weight, and lowers blood pressure compared to once-daily sitagliptin in patients with type 2 diabetes.Good
- Semaglutide treatment is associated with a higher risk of total adverse events and premature treatment discontinuation compared to sitagliptin, although the risk of serious adverse events is not significantly different.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →